Impact of Lipodystrophy on the Inflammatory State of Non-diabetic Dunnigan Reunion Island Subjects

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE LA RÉUNION · Oct 27, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effects of lipodystrophy, specifically Dunnigan Syndrome, on inflammation in patients who do not have diabetes. Researchers want to understand how this condition affects certain markers in the body that indicate inflammation. Previous studies have shown that people with Dunnigan Syndrome might have higher levels of these inflammatory markers compared to healthy individuals, but there are many factors, like smoking and other health conditions, that could influence these results. This study aims to gather more accurate data by focusing on individuals with Dunnigan Syndrome.

To participate, you need to be an adult over 18 years old who has been diagnosed with partial Dunnigan lipodystrophy. You should also be a member of a social security scheme and provide written consent to join the study. However, individuals who have diabetes, are pregnant or breastfeeding, have certain health issues, or smoke are not eligible. Participants can expect to undergo tests that will help researchers learn more about how lipodystrophy affects inflammation in the body, contributing to a better understanding of this rare condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult subject (\>18 years old) affected by partial Dunnigan lipodystrophy in the homozygous or heterozygous state (genetic search for the positive mutation carried out before inclusion in the study).
• • Person affiliated to or beneficiary of a social security scheme.
• • Free, informed and written consent signed by the participant and the investigator.
• Exclusion Criteria:
• • - Minor
• • Persons placed under judicial protection, person participating in another research including a period of exclusion still in progress, severely impaired physical and/or psychological health, which, according to the investigator, may affect the participant's compliance with the study
• • Previous known diabetes
• • Pregnant woman
• • Woman who gave birth less than 6 months ago
• • Breastfeeding in progress
• • Participation in other research that may have an impact on the evaluation of the main judgment criteria
• • Hemoglobin b level \< 7 mg/dl or \< 9-10 mg/dl for patients with cardiovascular or respiratory pathology.
• • Proven inflammatory pathologies
• • Anti-inflammatory treatment: taking corticosteroids in the last 3 months.
• • Active smoking